Biophysical characterisation, antitumor activity and MOF encapsulation of a half-sandwich ruthenium(ii) mitoxantronato system†
Abstract
The novel non-conventional metallodrug [(η6-p-cymene)2Ru2mitoxantronato]Cl2 (1) exhibits redox activity, DNA intercalation ability, cathepsin B and D inhibition and in vitro antitumor activity able to circumvent cisplatin resistance. Moreover, 1 can be successfully incorporated into MIL100(Fe) as a proof of concept of the feasibility of metal–organic frameworks as carriers of non-conventional drugs.
- This article is part of the themed collection: Emerging Investigators